NeuroCores, Inc.
Pre-clinical biotechnology company developing synthetic plasmalogen derivatives as therapeutics for rare pediatric neurological disorders (e.g., Rett syndrome, Leigh syndrome) and neurodegenerative diseases. Activities described on the site include medicinal chemistry of plasmalogen derivatives, preclinical in vivo efficacy and safety studies, analytical methods for plasmalogen detection, regulatory engagement for orphan/rare pediatric designations, and collaborations with academic research groups.
Industries
N/A
Products
KIT-13
A synthetic plasmalogen derivative developed as an orally administered small molecule intended to increase brain plasmalogen levels, reduce neuroinflammation, restore mitochondrial function, promote neurogenesis, and improve neuronal survival and function.
KIT-13
A synthetic plasmalogen derivative developed as an orally administered small molecule intended to increase brain plasmalogen levels, reduce neuroinflammation, restore mitochondrial function, promote neurogenesis, and improve neuronal survival and function.
Services
Research partnerships and collaboration
Collaborative R&D engagement model to work with academic institutions and external partners on plasmalogen research and therapeutic development.
Research partnerships and collaboration
Collaborative R&D engagement model to work with academic institutions and external partners on plasmalogen research and therapeutic development.
Expertise Areas
- Plasmalogen derivative therapeutics
- Preclinical and IND‑enabling development
- Neuroinflammation and neurodegeneration biology
- Medicinal chemistry and small-molecule design
Key Technologies
- Synthetic plasmalogen chemistry
- Oral small‑molecule therapeutic design
- Blood–brain barrier penetration optimization
- Animal disease models (Rett syndrome, Leigh syndrome, Alzheimer’s models)